Text and Data Mining valid from 2019-09-11
Received: 8 October 2018
Accepted: 4 September 2019
First Online: 11 September 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: <i>C. Pitsios, M. Tsoumani, M.B. Bilò, R. Gawlik, F. Rueff, G. Paraskevopoulos, E. Valovirta</i> and <i>M.A. Calderon</i> have no disclosures of interests to declare.<i>O. Pfaar</i> reports grants and personal fees from ALK-Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants from Biomay, grants from Nuvo, grants from Circassia, grants and personal fees from ASIT Biotech Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from Novartis Pharma, personal fees from MEDA Pharma, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Pohl-Boskamp, personal fees from Indoor Biotechnologies, grants from Glaxo Smith Kline, outside the submitted work.<i>G. Sturm</i> has received unrestricted research grant from ALK Abello, consulting and lecture fees from Novartis and Stallergens and lecture fees from Bencard, HAL and Allergopharma.<i>P. Demoly</i> has received personal fees for grants/lecture the past 2 years from AsraZeneca, Mylan, Sanofi, ASIT Biotech, ALK, StallergènesGreer, Thermofisher Scientific, Menarini, Chiesi, Bausch&Lomb, Yslab.<i>P. Rodruigez del Rio</i> has received personal lecture fees from GSK, FAES, Novartis, ALK-Abelló, Merck, HAL Allergy Group, LETI and Aimmune Therapeutics.